Intellia Therapeutics Inc (NASDAQ:NTLA) shares saw unusually-high trading volume on Thursday . Approximately 236,620 shares were traded during trading, a decline of 2% from the previous session’s volume of 241,794 shares.The stock last traded at $19.27 and had previously closed at $17.91.

NTLA has been the subject of a number of research analyst reports. Credit Suisse Group AG initiated coverage on shares of Intellia Therapeutics in a research note on Tuesday, May 31st. They set an “outperform” rating and a $39.00 price objective for the company. Jefferies Group initiated coverage on Intellia Therapeutics in a report on Tuesday, May 31st. They set a “hold” rating and a $33.00 target price for the company. Wedbush initiated coverage on Intellia Therapeutics in a report on Tuesday, May 31st. They set an “outperform” rating and a $38.00 target price for the company. Finally, Leerink Swann initiated coverage on Intellia Therapeutics in a report on Tuesday, May 31st. They set a “market perform” rating and a $32.00 target price for the company.

The stock has a 50 day moving average price of $23.22 and a 200 day moving average price of $24.47. The stock’s market capitalization is $665.93 million.

In other news, Director Carl L. Gordon bought 250,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 11th. The stock was acquired at an average price of $18.00 per share, with a total value of $4,500,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Bros. Advisors Lp Baker purchased 200,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 11th. The stock was bought at an average price of $18.00 per share, with a total value of $3,600,000.00. The disclosure for this purchase can be found here.

Intellia Therapeutics, Inc is a United States-based genome editing company focused on the development of curative therapeutics using a biological tool, CRISPR/Cas9 system. The Company’s CRISPR/Cas9 technology edits diseased genes in the human body through a single treatment course. It focuses on the therapeutic applications of CRISPR/Cas9 genome editing.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.